Sanofi and Novavax Inc. signed a licensing agreement that includes commercializing a combined Covid-19 and flu shot.
Vaccine-maker Novavax announced a $1.2 billion licensing partnership with French pharmaceutical company Sanofi on Friday, ...
Driving the news: Novavax will receive an upfront payment of $500 million and up to $700 million in milestone payments if ...
With flu and COVID hospital admission rates now mirroring each other, Novavax, which lost out in the COVID vaccine race to ...
Novavax shares jumped 50% on Monday following its recent licensing deal with Sanofi, as meme stocks are making a 2021-style ...
Novavax will only be able to offer a COVID-19 vaccine in the United States this autumn if regulators accept the shot it has ...
Novavax shares have soared and plummeted in recent years.
By Ben Glickman Shares of Novavax continued their ascent on Monday, adding to gains from last week after the company announced a licensing deal with ...
Novavax surpasses expectations in Q1 2024 results, while sealing a lucrative licensing agreement with Sanofi, spiking ...
Sanofi will also have a non-exclusive license to use the company’s Matrix-M adjuvant technology in other vaccine products. In return, Novavax is entitled to receive a milestone payment of up to $200 ...
Novavax ( NVAX -9.65%) has been a highly volatile stock in recent years, and that volatility is on full display again this ...
Novavax Novavax 0.0% stock has been weighed down in recent years due to a significant decline in Covid-19 vaccine demand.